Pin Oak Investment Advisors Inc. Acquires 82 Shares of Johnson & Johnson (NYSE:JNJ)

Pin Oak Investment Advisors Inc. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 6,895 shares of the company’s stock after buying an additional 82 shares during the period. Johnson & Johnson makes up approximately 1.0% of Pin Oak Investment Advisors Inc.’s holdings, making the stock its 20th biggest holding. Pin Oak Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $1,117,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Strategic Wealth Partners Ltd. boosted its holdings in shares of Johnson & Johnson by 26.7% in the 1st quarter. Strategic Wealth Partners Ltd. now owns 6,077 shares of the company’s stock valued at $961,000 after buying an additional 1,280 shares during the last quarter. Raelipskie Partnership lifted its stake in Johnson & Johnson by 3.9% in the first quarter. Raelipskie Partnership now owns 14,090 shares of the company’s stock valued at $2,229,000 after acquiring an additional 531 shares during the last quarter. Community Trust & Investment Co. grew its position in shares of Johnson & Johnson by 0.9% in the 1st quarter. Community Trust & Investment Co. now owns 96,066 shares of the company’s stock valued at $15,197,000 after acquiring an additional 877 shares during the period. Cetera Investment Advisers increased its stake in shares of Johnson & Johnson by 224.0% during the 1st quarter. Cetera Investment Advisers now owns 707,273 shares of the company’s stock worth $111,884,000 after purchasing an additional 488,955 shares during the last quarter. Finally, Cetera Advisors LLC raised its holdings in shares of Johnson & Johnson by 71.6% in the 1st quarter. Cetera Advisors LLC now owns 274,630 shares of the company’s stock valued at $43,444,000 after purchasing an additional 114,547 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 22.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

JNJ opened at $155.39 on Thursday. The firm has a market cap of $374.12 billion, a P/E ratio of 22.49, a price-to-earnings-growth ratio of 2.77 and a beta of 0.53. The business’s fifty day moving average is $159.52 and its 200-day moving average is $156.38. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the firm earned $2.66 EPS. Sell-side analysts expect that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.19%. Johnson & Johnson’s payout ratio is 71.78%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent analyst reports. Guggenheim boosted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Morgan Stanley increased their price target on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Seven research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $175.94.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.